--- title: "ABVC BioPharma (ABVC) news: Nasdaq notice" url: "https://aibio.space/companies/abvc-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABVC Nasdaq notice news: ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026. ABVC BioPharma, Inc." --- ABVC ABVC BioPharma, Inc. NASDAQ · United States # ABVC BioPharma (ABVC) news ABVC Nasdaq notice news Distress · 2026-05-15 ## [ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026](https://aibio.space/news/abvc-biopharma-files-nt-10-q-late-filing-notice-quarter-ended-march-31/) ABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period. ## Latest ABVC BioPharma news 1. 2025-04-30 Listings [ABVC BioPharma gets Nasdaq equity notice and sells 724,372 shares offshore](https://aibio.space/news/abvc-biopharma-gets-nasdaq-equity-notice-sells-724-372-shares-offshore/) ABVC reported stockholders' equity of $723,959, below the $2,500,000 Nasdaq minimum. It also sold shares to 15 non-U.S. buyers for a little more than $436,000. 2. 2025-03-31 Distress [ABVC BioPharma files NT 10-K late filing notice for 2024 annual report](https://aibio.space/news/abvc-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/) The company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results. 3. 2025-03-31 Distress [ABVC BioPharma delays annual report for fiscal year ended December 31, 2024](https://aibio.space/news/abvc-biopharma-delays-annual-report-fiscal-year-ended-december-31-2024/) ABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period. 4. 2025-01-06 Financings [ABVC BioPharma cuts warrant price to $0.40 as Lind agrees to exercise 1,029,167](https://aibio.space/news/abvc-biopharma-cuts-warrant-price-0-40-lind-agrees-exercise-1-029-167/) It is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing. ## ABVC BioPharma at a glance - **Ticker**: ABVC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $94,364 ### Related companies - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON - [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) NASDAQ: VRTX - [Veru](https://aibio.space/companies/veru/) NASDAQ: VERU - [Lyra Therapeutics](https://aibio.space/companies/lyra-therapeutics/) OTC: LYRA - [Harrow](https://aibio.space/companies/harrow/) NASDAQ: HROW - [Shuttle Pharmaceuticals Holdings](https://aibio.space/companies/shuttle-pharmaceuticals/) NASDAQ: SHPH - [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) NASDAQ: TTRX - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) NASDAQ: ACRV ### Also on NASDAQ - [OPKO HEALTH, INC.](https://aibio.space/companies/opko-health/) OPK - [Fate Therapeutics](https://aibio.space/companies/fate-therapeutics/) FATE - [Vyome Holdings](https://aibio.space/companies/vyome/) HIND - [WORK Medical Technology Group LTD](https://aibio.space/companies/work-medical-technology/) WOK - [Arrowhead Pharmaceuticals](https://aibio.space/companies/arrowhead-pharmaceuticals/) ARWR - [Aktis Oncology](https://aibio.space/companies/aktis-oncology/) AKTS ## ABVC BioPharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$509,589](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | | Research and development | [$121,085](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | [$179,272](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | | Net income (loss) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | [-$4.9 million](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | | Cash from operations | [-$3.0 million](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | [-$1.8 million](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/) | | Cash and equivalents | [$681,480](https://www.sec.gov/Archives/edgar/data/1173313/000121390026088348/) | [$248,382](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023062/) | | Short-term investments | [$64,354](https://www.sec.gov/Archives/edgar/data/1173313/000121390026088348/) | [$64,736](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023062/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $31,944, plus short-term investments of $62,420, $94,364 in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ABVC BioPharma Has ABVC BioPharma received a Nasdaq deficiency notice? Our latest story on this, dated May 15, 2026: "ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abvc-biopharma-files-nt-10-q-late-filing-notice-quarter-ended-march-31/). What is the ticker symbol of ABVC BioPharma? ABVC BioPharma, Inc. trades under the ticker ABVC on NASDAQ. Where is ABVC BioPharma listed? ABVC BioPharma, Inc. is listed on NASDAQ. What is the SEC CIK of ABVC BioPharma? The SEC Central Index Key (CIK) for ABVC BioPharma, Inc. is 1173313. Its filings are on SEC EDGAR. How many shares does ABVC BioPharma have outstanding? 26,654,365 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is ABVC BioPharma listed under? Our directory records ABVC BioPharma, Inc. under United States. What does ABVC BioPharma do? Our directory classifies ABVC BioPharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of ABVC BioPharma? The ISIN recorded for ABVC BioPharma, Inc. is US00091F3047. Does aibio.space cover ABVC BioPharma? aibio.space lists ABVC BioPharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ABVC BioPharma incorporated? SEC records list its state or country of incorporation as NV. Is ABVC BioPharma profitable? ABVC BioPharma, Inc. reported a net loss of $7.9 million for the fiscal year ended Dec 31, 2025, and used $3.0 million of cash in operations, per its annual report to the SEC. How much does ABVC BioPharma spend on research and development? $121,085 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does ABVC BioPharma have? $94,364 in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest ABVC BioPharma (ABVC) stock news? Our latest story on ABVC BioPharma, dated May 15, 2026: "ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026". ABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period. [Source](https://aibio.space/news/abvc-biopharma-files-nt-10-q-late-filing-notice-quarter-ended-march-31/). What is ABVC BioPharma's latest stock offering or financing news? Our latest financing story, dated Jan 6, 2025: "ABVC BioPharma cuts warrant price to $0.40 as Lind agrees to exercise 1,029,167". It is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing. [Source](https://aibio.space/news/abvc-biopharma-cuts-warrant-price-0-40-lind-agrees-exercise-1-029-167/). ## Investor discussion: ABVC BioPharma Members talk about ABVC BioPharma (ABVC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ABVC BioPharma, newest first. Each line links the filing it comes from. 1. 2026-08-27 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390026094152/ea0302908-8k_abvc.htm) 2. 2026-08-17 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390026090775/ea030229301-424b4_abvcbio.htm) 3. 2026-07-02 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390026074949/ea0296723-8k_abvcbio.htm) 4. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390026057917/ea0291128-nt10q_abvcbio.htm) 5. 2026-03-03 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 2.02,4.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390026023054/ea027914301ex99-1.htm) 6. 2025-11-14 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025110898/ea026489801-424b4_abvcbio.htm) 7. 2025-08-15 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025077473/ea025357801-424b4_abvc.htm) 8. 2025-04-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025037654/ea0239740-8k_abvcbio.htm) 9. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025035169/ea0239176-pre14a_abvc.htm) 10. 2025-04-15 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 2.02,4.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025032135/ea023837201ex99-1_abvcbio.htm) 11. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025026367/ea0236076-nt10k_abvcbio.htm) 12. 2025-01-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390025001211/ea0226487-8k_abvcbio.htm) 13. 2024-11-15 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390024099058/ea022131801-424b4_abvc.htm) 14. 2024-11-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1173313/000121390024094178/ea021970901-8k_abvcbio.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ABVC on TradingView](https://www.tradingview.com/symbols/NASDAQ-ABVC/). ## SEC filings and registration - **SEC name**: Abvc Biopharma, Inc. - **CIK**: 1173313 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ABVC (Nasdaq), ECOC (OTC) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 44370 OLD WARM SPRINGS BLVD., FREMONT, CA, 94538 - **Phone**: 510-668-0881 - **Shares outstanding**: 26,654,365 as of 2026-08-10 (10-Q filed 2026-08-12) - **Former names**: American BriVision (Holding) Corp; METU BRANDS, INC.; Ecology Coatings, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1173313/000121390026104509/ea0306577-def14a_abvc.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1173313/000121390026094152/ea0302908-8k_abvc.htm) filed 2026-08-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1173313/000121390026088348/ea0300204-10q_abvcbio.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1173313/000121390026084846/ea0300449-8k_abvcbio.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1173313/000121390026074949/ea0296723-8k_abvcbio.htm) filed 2026-07-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1173313/000121390026058104/ea0290931-10q_abvc.htm) filed 2026-05-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1173313/000121390026035499/ea028361801-8k_abvcbiopharm.htm) filed 2026-03-27 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1173313/000121390026024122/ea0279808-def14a_abvc.htm) filed 2026-03-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001173313), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ABVC BioPharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ABVC, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ABVC BioPharma, Inc. - **Ticker**: ABVC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00091F3047 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ABVC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/abvc-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ABVC BioPharma (ABVC) news: Nasdaq notice", 2026-10-31, https://aibio.space/companies/abvc-biopharma/